Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure

NACompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

April 30, 2009

Conditions
Liver Failure
Interventions
DEVICE

MARS device

10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.

PROCEDURE

Standard medical therapy

Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol

PROCEDURE

Standard medical therapy

Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol

Trial Locations (19)

1090

AKH Wien, Vienna

2100

Rigshospitalet Copenhagen, Copenhagen

3000

Universitaire Ziekenhuitzen, Leuven

8036

Hospital clinic, Barcelona

8091

Universitätshospital Zürich, Zurich

10117

Charite Berlin, Campus Mitte, Berlin

14004

Hospital Reina Sofia, Córdoba

18057

Uniklinik Rostock, Rostock

28007

Hospital General Universitario, Madrid

28034

Hospital Ramon y Cajal, Madrid

53105

Uniklinik Bonn, Bonn

59037

Hôpital Huriez, Lille

72076

Universitätsklinikum Tübingen, Tübingen

93053

Klinikum der Universität Regensburg, Regensburg

94800

Hôpital Paul Brousse, Villejuif

06097

Martin Luther Universität Halle-Wittenberg, Halle

00168

Catholic University of Rome, Rome

SE 5 9RS

King's College Hospital, London

WC1E 6HX

University College London, London

All Listed Sponsors
collaborator

2ConduCT

INDUSTRY

collaborator

G.E.M. mbh Meerbusch

OTHER

collaborator

DatInf

UNKNOWN

collaborator

Gambro Lundia AB

INDUSTRY

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY

NCT00614146 - Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure | Biotech Hunter | Biotech Hunter